Skip to content
Screener

Guardant Health GH Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$0
GRAIL, Inc. logo
GRAIL, Inc.GRAL
$00.0%
Myriad Genetics logo
Myriad GeneticsMYGN
NeoGenomics logo
NeoGenomicsNEO
Veracyte logo
VeracyteVCYT

Other financials

Income statement

See full
Revenue$301.7M+48.3%
Gross profit$196.7M+52.8%
Operating income-$121.4M-9.3%
Net income-$112.1M-17.8%
EPS (diluted)-$0.85-10.4%

Balance sheet

See full
Cash & equivalents$1.1B+37.0%
Total debt$1.7B+30.5%
Total equity-$181.1M+27.8%
Total assets$1.9B+42.5%

Cash flow

See full
Operating cash flow-$65.6M-4.7%
CapEx$5.6M+25.1%
Free cash flow-$71.2M-6.0%

Valuation

See full
Market cap$22.61B+231%
Enterprise value$23.21B+212%
P/S20.9×+12.7×

Profitability

See full
Gross margin64.9%+3.6pp
Operating margin-41.4%-9.4pp
Net margin-40.1%-8.1pp
FCF margin-22%-6.7pp

Returns & leverage

See full
Return on equity-438.1%-1,655pp
Debt / equity
Current ratio4.7×+0.6×

Where this comes from

Reported directly by Guardant Health in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Guardant Health’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 5:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001576280-26-000026
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 131,514,404 and 130,635,301 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively11
Additional paid-in capital2,930,6652,900,056
Accumulated other comprehensive loss(5,152)(4,852)
Accumulated deficit(3,106,587)(2,994,512)
Total Stockholders’ Deficit(181,073)(99,307)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Guardant Health's common stock, par value (in dollars per share)?
Guardant Health (GH) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has Guardant Health's common stock, par value (in dollars per share) changed year-over-year?
Guardant Health's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Guardant Health's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Guardant Health's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Ask your AI about Guardant Health's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude